Dicker Frank, Kater Arnon P, Prada Carlos E, Fukuda Tetsuya, Castro Januario E, Sun Guizhen, Wang Jean Y, Kipps Thomas J
Moores Cancer Center, University of California-San Diego School of Medicine, La Jolla, CA 92093-0663, USA.
Blood. 2006 Nov 15;108(10):3450-7. doi: 10.1182/blood-2006-04-017749. Epub 2006 Jun 1.
Intravenous infusion of autologous chronic lymphocytic leukemia (CLL) cells transduced with an adenovirus encoding CD40-ligand (CD154) caused rapid reductions in leukemia-cell counts and lymphnode size. We hypothesized that CD40-ligation via CD154 sensitized CLL cells to death-receptor-mediated apoptosis. We found that CD154-expressing cells induced expression of CD95 and the BH3-interacting-domain death agonist (Bid) in CLL, regardless of whether the leukemia cells had functional p53. Such treatment also induced p73, a p53-related transcription factor regulated by c-Abl kinase, and enhanced the sensitivity to fludarabine (F-ara-A) of CLL cells lacking functional p53. Transduction of CLL cells with an adenovirus encoding p73 also induced Bid and CD95 and enhanced the sensitivity to F-ara-A of p53-deficient CLL cells. However, inhibition of c-Abl with imatinib suppressed CD154-induced expression of p73, p73-induced expression of Bid and CD95, and blocked the sensitization of p53-deficient CLL cells to CD95-mediated or F-ara-A-induced apoptosis. Conversely, CLL cells transduced with an imatinib-resistant c-Abl mutant could be induced by CD154 to express p73 and Bid even when treated with imatinib. These results indicate that CD154 can sensitize leukemia cells to apoptosis via the c-Abl-dependent activation of p73 and mitigate the resistance of p53-deficient CLL cells to anticancer drug therapy.
静脉输注用编码CD40配体(CD154)的腺病毒转导的自体慢性淋巴细胞白血病(CLL)细胞,可使白血病细胞计数和淋巴结大小迅速降低。我们推测,通过CD154进行的CD40连接使CLL细胞对死亡受体介导的凋亡敏感。我们发现,表达CD154的细胞可诱导CLL细胞中CD95和BH3相互作用结构域死亡激动剂(Bid)的表达,无论白血病细胞是否具有功能性p53。这种处理还可诱导p73,一种受c-Abl激酶调节的p53相关转录因子,并增强缺乏功能性p53的CLL细胞对氟达拉滨(F-ara-A)的敏感性。用编码p73的腺病毒转导CLL细胞也可诱导Bid和CD95,并增强p53缺陷型CLL细胞对F-ara-A的敏感性。然而,用伊马替尼抑制c-Abl可抑制CD154诱导的p73表达、p73诱导的Bid和CD95表达,并阻断p53缺陷型CLL细胞对CD95介导的或F-ara-A诱导的凋亡的敏感性。相反,用伊马替尼耐药的c-Abl突变体转导的CLL细胞即使在用伊马替尼处理时也可被CD154诱导表达p73和Bid。这些结果表明,CD154可通过c-Abl依赖的p73激活使白血病细胞对凋亡敏感,并减轻p53缺陷型CLL细胞对抗癌药物治疗的耐药性。